Merck KGaA (MKGAF) Stock Price, News & Analysis

Company Overview

Merck KGaA is a science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it is distinct from the U.S.-based Merck & Co. and operates internationally across healthcare, life science and electronics.

Its Healthcare business develops prescription medicines, including treatments in areas such as oncology, neurology, immunology and fertility. The Life Science business supplies products and services used in research, biotechnology and pharmaceutical manufacturing, including laboratory materials, equipment and solutions for bioprocessing.

Through its Electronics business, Merck provides specialty materials and technologies used in semiconductor and display manufacturing. The company serves customers worldwide, combining pharmaceutical development with products and services for scientific research and advanced technology industries.

Key Stats

• Today's Range: $162.12 to $169.66
• 50-Day Range: $149.97 to $170.10
• 52-Week Range: $116.68 to $175.56
• Volume: 1,049 shs
• Average Volume: 610 shs
• Market Capitalization: $21.60 billion
• P/E Ratio: 25.51
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Merck KGaA Stock Analysis - MarketRank™

Merck KGaA scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Merck KGaA.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 8.21%

Earnings Growth

Earnings for Merck KGaA are expected to grow by 8.21% in the coming year, from $9.75 to $10.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Merck KGaA is 25.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.40.

Price to Earnings Ratio vs. Sector

The P/E ratio of Merck KGaA is 25.51, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.56.

Price to Book Value per Share Ratio

Merck KGaA has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.51% of the float of Merck KGaA has been sold short.

Short Interest Ratio / Days to Cover

Merck KGaA has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Merck KGaA has recently increased by 3.39%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Merck KGaA does not currently pay a dividend.

Dividend Growth

Merck KGaA does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.08

News Sentiment

Merck KGaA has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Merck KGaA this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Merck KGaA insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.10% of the stock of Merck KGaA is held by institutions.

Company Calendar

• Today: 11/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:MKGAF
• CIK: N/A
• Web: www.merckgroup.com
• Phone: 496151720
• Fax: 49-61-5172-2000
• Employees: 62,461
• Year Founded: 1891

Profitability

• EPS (Trailing Twelve Months): $6.81
• Trailing P/E Ratio: 25.51
• Forward P/E Ratio: 15.84
• P/E Growth: N/A
• Net Income: $3.06 billion
• Net Margins: 12.60%
• Pretax Margin: 15.64%
• Return on Equity: 10.17%
• Return on Assets: 5.74%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 1.31
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $22.72 billion
• Price / Sales: 0.95
• Cash Flow: $50.34 per share
• Price / Cash Flow: 3.32
• Book Value: $212.00 per share
• Price / Book: 0.79

Miscellaneous

• Outstanding Shares: 129,240,000
• Free Float: N/A
• Market Cap: $21.60 billion
• Optionable: Not Optionable
• Beta: 0.96